vs
LandBridge Co LLC（LB）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是LandBridge Co LLC的1.2倍（$69.8M vs $56.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 14.2%，领先369.8%），LandBridge Co LLC同比增速更快（55.6% vs 21.2%），过去两年LandBridge Co LLC的营收复合增速更高（72.8% vs 53.7%）
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
LB vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.2倍
$56.8M
营收增速更快
LB
高出34.4%
21.2%
净利率更高
RIGL
高出369.8%
14.2%
两年增速更快
LB
近两年复合增速
53.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $56.8M | $69.8M |
| 净利润 | $8.1M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 60.0% | 33.2% |
| 净利率 | 14.2% | 384.0% |
| 营收同比 | 55.6% | 21.2% |
| 净利润同比 | -83.7% | 1769.2% |
| 每股收益（稀释后） | $0.24 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LBRIGL
| Q4 25 | $56.8M | $69.8M | ||
| Q3 25 | $50.8M | $69.5M | ||
| Q2 25 | $47.5M | $101.7M | ||
| Q1 25 | $44.0M | $53.3M | ||
| Q4 24 | $36.5M | $57.6M | ||
| Q3 24 | $28.5M | $55.3M | ||
| Q2 24 | $26.0M | $36.8M | ||
| Q1 24 | $19.0M | $29.5M |
净利润LBRIGL
| Q4 25 | $8.1M | $268.1M | ||
| Q3 25 | $8.1M | $27.9M | ||
| Q2 25 | $7.5M | $59.6M | ||
| Q1 25 | $6.5M | $11.4M | ||
| Q4 24 | $49.3M | $14.3M | ||
| Q3 24 | $2.7M | $12.4M | ||
| Q2 24 | $-57.7M | $-1.0M | ||
| Q1 24 | $10.8M | $-8.2M |
毛利率LBRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率LBRIGL
| Q4 25 | 60.0% | 33.2% | ||
| Q3 25 | 60.8% | 40.9% | ||
| Q2 25 | 60.0% | 60.1% | ||
| Q1 25 | 57.0% | 23.9% | ||
| Q4 24 | 49.4% | 28.9% | ||
| Q3 24 | 11.2% | 25.4% | ||
| Q2 24 | -197.4% | 1.2% | ||
| Q1 24 | 71.1% | -23.6% |
净利率LBRIGL
| Q4 25 | 14.2% | 384.0% | ||
| Q3 25 | 15.9% | 40.2% | ||
| Q2 25 | 15.8% | 58.6% | ||
| Q1 25 | 14.7% | 21.5% | ||
| Q4 24 | 135.2% | 24.9% | ||
| Q3 24 | 9.3% | 22.5% | ||
| Q2 24 | -222.1% | -2.8% | ||
| Q1 24 | 56.7% | -27.9% |
每股收益（稀释后）LBRIGL
| Q4 25 | $0.24 | $14.11 | ||
| Q3 25 | $0.26 | $1.46 | ||
| Q2 25 | $0.24 | $3.28 | ||
| Q1 25 | $0.20 | $0.63 | ||
| Q4 24 | — | $0.82 | ||
| Q3 24 | $-0.04 | $0.70 | ||
| Q2 24 | — | $-0.06 | ||
| Q1 24 | — | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $30.7M | $155.0M |
| 总债务越低越好 | $570.7M | $52.5M |
| 股东权益账面价值 | $340.3M | $391.5M |
| 总资产 | $1.4B | $513.6M |
| 负债/权益比越低杠杆越低 | 1.68× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资LBRIGL
| Q4 25 | $30.7M | $155.0M | ||
| Q3 25 | $28.3M | $137.1M | ||
| Q2 25 | $20.3M | $108.4M | ||
| Q1 25 | $14.9M | $77.1M | ||
| Q4 24 | $37.0M | $77.3M | ||
| Q3 24 | $14.4M | $61.1M | ||
| Q2 24 | $24.6M | $49.1M | ||
| Q1 24 | — | $49.5M |
总债务LBRIGL
| Q4 25 | $570.7M | $52.5M | ||
| Q3 25 | $366.1M | $60.0M | ||
| Q2 25 | $370.9M | $60.0M | ||
| Q1 25 | $375.5M | $60.0M | ||
| Q4 24 | $385.5M | $60.0M | ||
| Q3 24 | $242.4M | $60.0M | ||
| Q2 24 | $360.8M | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益LBRIGL
| Q4 25 | $340.3M | $391.5M | ||
| Q3 25 | $272.0M | $117.6M | ||
| Q2 25 | $266.4M | $81.9M | ||
| Q1 25 | $217.0M | $18.6M | ||
| Q4 24 | $211.8M | $3.3M | ||
| Q3 24 | $97.2M | $-14.6M | ||
| Q2 24 | $296.4M | $-29.9M | ||
| Q1 24 | $162.3M | $-31.7M |
总资产LBRIGL
| Q4 25 | $1.4B | $513.6M | ||
| Q3 25 | $1.1B | $242.5M | ||
| Q2 25 | $1.1B | $206.7M | ||
| Q1 25 | $1.0B | $176.0M | ||
| Q4 24 | $1.0B | $164.0M | ||
| Q3 24 | $689.9M | $139.4M | ||
| Q2 24 | $710.5M | $128.4M | ||
| Q1 24 | — | $126.5M |
负债/权益比LBRIGL
| Q4 25 | 1.68× | 0.13× | ||
| Q3 25 | 1.35× | 0.51× | ||
| Q2 25 | 1.39× | 0.73× | ||
| Q1 25 | 1.73× | 3.23× | ||
| Q4 24 | 1.82× | 18.25× | ||
| Q3 24 | 2.49× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.3M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $122.0M | — |
| 自由现金流率自由现金流/营收 | 214.9% | — |
| 资本支出强度资本支出/营收 | 7.5% | — |
| 现金转化率经营现金流/净利润 | 15.68× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $207.7M | — |
8季度趋势，按日历期对齐
经营现金流LBRIGL
| Q4 25 | $126.3M | $22.0M | ||
| Q3 25 | $34.9M | $24.0M | ||
| Q2 25 | $37.3M | $30.5M | ||
| Q1 25 | $15.9M | $-893.0K | ||
| Q4 24 | $67.6M | $14.5M | ||
| Q3 24 | $7.5M | $21.7M | ||
| Q2 24 | $16.0M | $302.0K | ||
| Q1 24 | $17.2M | $-5.0M |
自由现金流LBRIGL
| Q4 25 | $122.0M | — | ||
| Q3 25 | $33.7M | — | ||
| Q2 25 | $36.1M | — | ||
| Q1 25 | $15.8M | — | ||
| Q4 24 | $66.7M | — | ||
| Q3 24 | $7.1M | — | ||
| Q2 24 | $15.7M | — | ||
| Q1 24 | $17.1M | — |
自由现金流率LBRIGL
| Q4 25 | 214.9% | — | ||
| Q3 25 | 66.3% | — | ||
| Q2 25 | 75.9% | — | ||
| Q1 25 | 36.0% | — | ||
| Q4 24 | 182.6% | — | ||
| Q3 24 | 25.1% | — | ||
| Q2 24 | 60.4% | — | ||
| Q1 24 | 90.1% | — |
资本支出强度LBRIGL
| Q4 25 | 7.5% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 2.7% | — | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 0.5% | — |
现金转化率LBRIGL
| Q4 25 | 15.68× | 0.08× | ||
| Q3 25 | 4.31× | 0.86× | ||
| Q2 25 | 4.98× | 0.51× | ||
| Q1 25 | 2.46× | -0.08× | ||
| Q4 24 | 1.37× | 1.01× | ||
| Q3 24 | 2.80× | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
